Abstract

Purpose: Whether tamoxifen affects the risk of neurodegenerative disease is controversial. This nationwide population-based study investigated the risk of Parkinson’s disease (PD) associated with tamoxifen treatment in female patients with breast cancer using Taiwan’s National Health Insurance Research Database. Methods: A total of 5,185 and 5,592 female patients with breast cancer who did and did not, respectively, receive tamoxifen treatment between 2000 and 2009 were included in the study. Patients who subsequently developed PD were identified. A Cox proportional hazards model was used to compare the risk of PD between the aforementioned groups. Results: Tamoxifen did not significantly increase the crude rate of developing PD in female patients with breast cancer (tamoxifen group, 16/5,169; non-tamoxifen group, 11/5,581; p=0.246). Tamoxifen did not significantly increase the adjusted hazard ratio (aHR) for subsequently developing PD (aHR, 1.310; 95% confidence interval [CI], 0.605–2.837; p= 0.494). However, tamoxifen significantly increased the risk of PD among patients followed up for more than 6 years (aHR, 2.435; 95% CI, 1.008–5.882; p=0.048). Conclusion: Tamoxifen treatment may increase the risk of PD in Taiwanese female patients with breast cancer more than 6 years after the initiation of treatment.

Original languageEnglish
Pages (from-to)356-360
Number of pages5
JournalJournal of Breast Cancer
Volume20
Issue number4
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Tamoxifen
Parkinson Disease
Breast Neoplasms
Population
Confidence Intervals
National Health Programs
Therapeutics
Proportional Hazards Models
Neurodegenerative Diseases
Databases
Research

Keywords

  • Breast neoplasms
  • Parkinson disease
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{a5aadf33175449f7904b829689fc26ae,
title = "Tamoxifen and the risk of Parkinson’s disease in female patients with breast cancer in asian people: A nationwide population-based study",
abstract = "Purpose: Whether tamoxifen affects the risk of neurodegenerative disease is controversial. This nationwide population-based study investigated the risk of Parkinson’s disease (PD) associated with tamoxifen treatment in female patients with breast cancer using Taiwan’s National Health Insurance Research Database. Methods: A total of 5,185 and 5,592 female patients with breast cancer who did and did not, respectively, receive tamoxifen treatment between 2000 and 2009 were included in the study. Patients who subsequently developed PD were identified. A Cox proportional hazards model was used to compare the risk of PD between the aforementioned groups. Results: Tamoxifen did not significantly increase the crude rate of developing PD in female patients with breast cancer (tamoxifen group, 16/5,169; non-tamoxifen group, 11/5,581; p=0.246). Tamoxifen did not significantly increase the adjusted hazard ratio (aHR) for subsequently developing PD (aHR, 1.310; 95{\%} confidence interval [CI], 0.605–2.837; p= 0.494). However, tamoxifen significantly increased the risk of PD among patients followed up for more than 6 years (aHR, 2.435; 95{\%} CI, 1.008–5.882; p=0.048). Conclusion: Tamoxifen treatment may increase the risk of PD in Taiwanese female patients with breast cancer more than 6 years after the initiation of treatment.",
keywords = "Breast neoplasms, Parkinson disease, Tamoxifen",
author = "Hong, {Chien Tai} and Lung Chan and Hu, {Chaur Jong} and Lin, {Chien Min} and Hsu, {Chien Yeh} and Lin, {Ming Chin}",
year = "2017",
month = "12",
day = "1",
doi = "10.4048/jbc.2017.20.4.356",
language = "English",
volume = "20",
pages = "356--360",
journal = "Journal of Breast Cancer",
issn = "1738-6756",
publisher = "Korean Breast Cancer Society",
number = "4",

}

TY - JOUR

T1 - Tamoxifen and the risk of Parkinson’s disease in female patients with breast cancer in asian people

T2 - A nationwide population-based study

AU - Hong, Chien Tai

AU - Chan, Lung

AU - Hu, Chaur Jong

AU - Lin, Chien Min

AU - Hsu, Chien Yeh

AU - Lin, Ming Chin

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Purpose: Whether tamoxifen affects the risk of neurodegenerative disease is controversial. This nationwide population-based study investigated the risk of Parkinson’s disease (PD) associated with tamoxifen treatment in female patients with breast cancer using Taiwan’s National Health Insurance Research Database. Methods: A total of 5,185 and 5,592 female patients with breast cancer who did and did not, respectively, receive tamoxifen treatment between 2000 and 2009 were included in the study. Patients who subsequently developed PD were identified. A Cox proportional hazards model was used to compare the risk of PD between the aforementioned groups. Results: Tamoxifen did not significantly increase the crude rate of developing PD in female patients with breast cancer (tamoxifen group, 16/5,169; non-tamoxifen group, 11/5,581; p=0.246). Tamoxifen did not significantly increase the adjusted hazard ratio (aHR) for subsequently developing PD (aHR, 1.310; 95% confidence interval [CI], 0.605–2.837; p= 0.494). However, tamoxifen significantly increased the risk of PD among patients followed up for more than 6 years (aHR, 2.435; 95% CI, 1.008–5.882; p=0.048). Conclusion: Tamoxifen treatment may increase the risk of PD in Taiwanese female patients with breast cancer more than 6 years after the initiation of treatment.

AB - Purpose: Whether tamoxifen affects the risk of neurodegenerative disease is controversial. This nationwide population-based study investigated the risk of Parkinson’s disease (PD) associated with tamoxifen treatment in female patients with breast cancer using Taiwan’s National Health Insurance Research Database. Methods: A total of 5,185 and 5,592 female patients with breast cancer who did and did not, respectively, receive tamoxifen treatment between 2000 and 2009 were included in the study. Patients who subsequently developed PD were identified. A Cox proportional hazards model was used to compare the risk of PD between the aforementioned groups. Results: Tamoxifen did not significantly increase the crude rate of developing PD in female patients with breast cancer (tamoxifen group, 16/5,169; non-tamoxifen group, 11/5,581; p=0.246). Tamoxifen did not significantly increase the adjusted hazard ratio (aHR) for subsequently developing PD (aHR, 1.310; 95% confidence interval [CI], 0.605–2.837; p= 0.494). However, tamoxifen significantly increased the risk of PD among patients followed up for more than 6 years (aHR, 2.435; 95% CI, 1.008–5.882; p=0.048). Conclusion: Tamoxifen treatment may increase the risk of PD in Taiwanese female patients with breast cancer more than 6 years after the initiation of treatment.

KW - Breast neoplasms

KW - Parkinson disease

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=85039747565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039747565&partnerID=8YFLogxK

U2 - 10.4048/jbc.2017.20.4.356

DO - 10.4048/jbc.2017.20.4.356

M3 - Article

AN - SCOPUS:85039747565

VL - 20

SP - 356

EP - 360

JO - Journal of Breast Cancer

JF - Journal of Breast Cancer

SN - 1738-6756

IS - 4

ER -